| Quantity | Price | Total |
|---|---|---|
| 2 – 15 IU Vials | $425.00 | $850.00 |
| 4 – 15 IU Vials | $395.00 | $1,580.00 |
| 6 – 15 IU Vials | $375.00 | $2,250.00 |
HGH for Sale As low as $25 per IU!
| Quantity | Price | Total |
|---|---|---|
| 1 – 36 IU Vial | $825.00 | $825.00 |
| 3 – 36 IU Vials | $795.00 | $2,385.00 |
| 5 – 36 IU Vials | $775.00 | $3,875.00 |
HGH for Sale As low as $25 per IU!
Humatrope® is an FDA-approved human growth hormone (HGH) injection developed by Eli Lilly to treat growth hormone deficiency (GHD) in children and adults. Since 1987, it has been a trusted HGH therapy for individuals with idiopathic short stature (ISS), Turner syndrome, SHOX deficiency, and small for gestational age (SGA).
Humatrope® promotes height growth, muscle development, and overall well-being. This clinically tested HGH solution is available in cartridges and HumatroPen® injection devices for easy administration. Looking to buy Humatrope® online? We offer fast U.S. delivery and competitive pricing.
Humatrope® is a clinically tested, FDA-approved human growth hormone (HGH) injection designed to treat growth hormone deficiency (GHD) in children and adults. Manufactured by Eli Lilly, it is available in cartridges, HumatroPen® injection devices, and vials for easy administration.
With decades of medical research, Humatrope® is one of the most recommended HGH treatments for height growth, muscle development, and metabolic support. Your dosage is determined based on age, weight, and medical condition, ensuring safe and effective results.
Humatrope® HGH is an FDA-approved treatment designed to enhance linear growth, metabolism, and overall health. Whether used for children with growth hormone deficiency or adults seeking metabolic support, Humatrope® ensures effective results with clinical validation.
Humatrope® stimulates skeletal growth in pediatric patients with growth hormone deficiency. The measurable increase in body length after administration of either Humatrope® or human growth hormone of pituitary origin results from an effect on the growth plates of long bones. Concentrations of IGF–1, which may play a role in skeletal growth, are low in the serum of growth hormone–deficient pediatric patients but increase during treatment with Humatrope®.
Linear growth is facilitated in part by increased cellular protein synthesis. Nitrogen retention, as demonstrated by decreased urinary nitrogen excretion and serum urea nitrogen, follows the initiation of therapy with human growth hormone of pituitary origin. Treatment with Humatrope results in a similar decrease in serum urea nitrogen.
Pediatric patients with hypopituitarism sometimes experience fasting hypoglycemia that is improved by treatment with Humatrope. Large doses of human growth hormone may impair glucose tolerance. Untreated patients with Turner syndrome have an increased incidence of glucose intolerance.
In growth hormone–deficient patients, administration of human growth hormone of pituitary origin has resulted in lipid mobilization, reduction in body fat stores, and increased plasma fatty acids.
Retention of sodium, potassium, and phosphorus is induced by human growth hormone of pituitary origin. Serum concentrations of inorganic phosphate increased in patients with growth hormone deficiency after therapy with Humatrope® or human growth hormone of pituitary origin. Serum calcium is not significantly altered in patients treated with either human growth hormone of pituitary origin or Humatrope®.
Individual customer feedback. Reviews are not medical evidence or a guarantee of results.
HGH Sells provides product and pricing information for adults in the United States. Human growth hormone and GLP-1 medications are prescription products. Product information on this website is educational and commercial information and is not a substitute for diagnosis, treatment, or advice from a licensed healthcare professional. Manufacturer names and trademarks belong to their respective owners; HGH Sells is not the manufacturer of the products displayed.
